Cargando…
SUN-694 Case Study of Nonalcoholic Steatohepatitis Reversibility in Type Two Diabetic Patient with Weight Loss Using Liraglutide
Introduction Nonalcoholic fatty liver disease (NAFLD) is a common form of chronic liver disease.(1) NAFLD prevalence is likely to be between 75- 100% in the morbidity obese. Where Nonalcoholic steatohepatitis (NASH) in turns develops in 30% of patients with NAFLD. Obesity prevalence in Kuwait is est...
Autores principales: | Shaghouli, Amna Ali, Aranky, Rola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207809/ http://dx.doi.org/10.1210/jendso/bvaa046.1801 |
Ejemplares similares
-
SUN-682 Type Two Diabetes Patient in Remission After Twelve Years of Diagnosis
por: Shaghouli, Amna Ali, et al.
Publicado: (2020) -
MON-LB032 Real World Evidence Data on the Role of Sodium/Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonist in Chronic Kidney Disease Stage 3 Patients beyond Glycemic Control, at Glycemia Clinic- Kuwait
por: Shaghouli, Amna, et al.
Publicado: (2019) -
Management of Late Dumping Syndrome Induced Hypoglycemia With GLP-1R Agonist
por: Shaghouli, Amna Ali, et al.
Publicado: (2021) -
SUN-178 A Not So "Sweet" DKA: A Case of Euglycemic Diabetic Ketoacidosis Caused by Dapagliflozin/Liraglutide Combination
por: Sideri Gugger, Aristea, et al.
Publicado: (2019) -
MON-694 EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i
por: Heckart, Jonathan Calvin, et al.
Publicado: (2020)